Korea Readying Itself For New Era Of Digital Therapeutics
Pivotal Trials Underway But Reimbursement Lacking
Executive Summary
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.
You may also be interested in...
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.